Entrar/Registro  
INICIO ENGLISH
 
Anales Médicos de la Asociación Médica del Centro Médico ABC
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Anales Médicos de la Asociación Médica del Centro Médico ABC >Año 2012, No. 2


D’Hyver DJWC
Tratamiento de la osteoporosis en pacientes postoperados de fracturas
An Med Asoc Med Hosp ABC 2012; 57 (2)

Idioma: Español
Referencias bibliográficas: 45
Paginas: 136-143
Archivo PDF: 121.21 Kb.


Texto completo




RESUMEN

En las personas de edad avanzada observamos con frecuencia la aparición de fracturas secundarias a la osteoporosis; el tratamiento quirúrgico de éstas, en especial, las que ocurren en la cadera, puede lograr que la intervención sea un éxito a través del tiempo, mediante la intervención farmacológica y no farmacológica de la osteoporosis. Los bifosfonatos no son siempre la mejor elección o la primera para su uso, conocer las alternativas y poder seleccionar la mejor opción para cada uno de los pacientes es un reto para el cirujano ortopedista. Se presenta una pequeña revisión de lo que es la osteoporosis, sus factores de riesgo, el diagnóstico y las herramientas terapéuticas para su manejo; de una manera simple, el árbol de decisiones permite reconocer las opciones para la adecuada selección del manejo.


Palabras clave: Osteoporosis, tratamiento, postquirúrgico.


REFERENCIAS

  1. Consensus conference: from the national institutes of health. JAMA 2001; 285 (6)14: 785-795.

  2. Kenny A. Osteoporosis, pathogenesis, diagnosis, and treatment in older adults. Rheum Dis Clin North Am 2000; 26 (3): 569-591.

  3. Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin N Am 2006; 32: 617-629.

  4. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11: 669-674.

  5. Van Staa TP, Dennison EM, Leufkens HGM et al. Epidemiology of fractures in England and Wales. Bone 2001; 29: 517-522.

  6. Kenny A, Prestwood K. Osteoporosis, pathogenesis, diagnosis and treatment in older adults. Rheum Dis Clin of North Am 2000; 26 (3): 569-591.

  7. Wade J. Osteoporosis review basics. Can Med Assoc 2001; 165 (1): 45-50.

  8. University of Michigan Health System (UMHS) Osteoporosis: prevention and treatment. ANN Arbor (MI): University of Michigan Health System; 2010: 15.

  9. American College of Preventive Medicine (ACPM). Screening for osteoporosis in the adult U.S. population: ACPM position statement preventive practice. Am J Prev Med 2009; 36 (4): 366-375.

  10. Internet Citation National Guideline Clearinghouse (NGC). Guideline synthesis: Screening and risk assessment for osteoporosis in postmenopausal women. In: National Guideline Clearinghouse (NGC) (Web Site). Rockville (MD): 2008 Apr (revised 2011 Jan). Available: http://www.guideline.gov

  11. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17 (1645): 1652.

  12. Majumdar SR, Rowe BH, Folk D, Johnson JA, Holroyd BH, Morrish DW, Maksymowych WP, Steiner IP, Harley CH, Wirzba BJ, Hanley DA, Blitz S, Russell AS. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med 2004; 141 (5): 366-373.

  13. Edwards BJ, Bunta AD, Madison LD, DeSantis A, Ramsey-Goldman R, Taft L, Wilson C, Moinfar M. An osteoporosis and fracture intervention program increases the diagnosis and treatment for osteoporosis for patients with minimal trauma fractures. Jt Comm J Qual Patient Saf 2005; 31 (5): 267-274.

  14. Sale EMJ, Gignac AM, Hawker G, Frankell L, Beatón D, Bogoch E, Elliot-Gibson V. Decision to take osteoporosis medication in patients who have had a fracture and are “high” risk for future fracture: A qualitative study. BMC Musculoskelet Disord 2011; 12: 92.

  15. Mullen JO, Mullen NL. Hip fracture mortality. A prospective, multifactorial study to predict and minimize death risk. Clin Orthop Relat Res 1992; 280: 214-222.

  16. Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of quality following hip fracture: a prospective study. Osteoporos Int 2000; 11: 460-466.

  17. Colon-Emeric CS, Sloane R, Hawkes WG, Magaziner J, Zimmerman SI, Pieper CF, Lyles KW. The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture. Am J Med 2000; 109: 324-326.

  18. Melton LJ 3rd, Ilstrup DM, Beckenbaugh RD, Riggs BL. Hip fracture recurrence. A population-based study. Clin Orthop Relat Res 1982; 167: 131-138.

  19. Juby AG, De Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 2002; 13: 205-210.

  20. Siris ES, Bilezikian JP, Rubin MR, Black DM, Bockman RS, Bone HG, Hochberg MC, McClung MR, Schnitzer TJ. Pins and plaster aren’t enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003; 88: 3482-3486.

  21. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541.

  22. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357: nihpa40967.

  23. Kim TY, Ha YC, Kim YH, Lee SR, Kim SR, Kim JR, Kim SY, Koo KH. Treatment of osteoporosis after hip fractures in patients older than 50 years. J Korean Hip Soc 2007; 19: 499-503.

  24. Miki RA, Oetgen ME, Kirk J, Insogna KL, Lindskog DM. Orthopedic management improves the rate of early osteoporosis treatment after hip fracture. A randomized clinical trial. J Bone Joint Surg Am 2008; 90: 2346-2353.

  25. Goldhahn J, Blauth M. Osteoporotic fracture management: closing the gap of knowledge. Arch Orthop Trauma Surg 2007; 127: 1-2.

  26. Sang-Rim Kim, Yong-Chan Ha, Yong-Geun Park, Sung-Rak Lee, Kyung-Hoi Koo. Orthopedic surgeon’s awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study. J Korean Med Sci 2011; 26: 1501-1507.

  27. Cornell CN. Internal fracture fixation in patients whit osteoporosis. J Am Acad Orthop Surg 2003; 11: 109-119.

  28. Yates JE, Hadi SS, Blackwell JC. Clinical inquiries do NSAIDs impede fracture healing? J Fam Pract 2011; 60: 40-42.

  29. Amanat N, Mcdonald M, Godfrey C et al. Optimal timing of a single dose of soledronic acid to increase strength in rat fracture repare. J Bone Miner Res 2007; 22: 867-876.

  30. Leanart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. J Engl J Med 2008; 358: 1304-1306.

  31. Yli-Kyyny T. Bisphosphonates and atypical fractures or femur. J Osteoporosis 2011, Article ID 7549972: 5.

  32. www.fda.gob/consumer. Possible fracture risk with osteoporosis drugs. 2010.

  33. Fraser LA, Vogt KN, Adachi JD, Thabane L. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis a systematic review and meta-analysis. Ther Clin Risk Manag 2011; 7: 157-166.

  34. Gestenfeld LC, Sacks DJ, Pelis M et al. Comparison of effects of the bisphosphonate alendronate vs the RANKL inhibitor denosumab on murine fracture lealing. J Bone Miner Res 2009; 24: 196-208.

  35. Adami S, Adachi J, Boonen S et al. Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res 2010; 25 Suppl 1: MO0405.

  36. Stuermer EK, Sehmisch S, Rack T et al. Estrogen and raloxifene improve metaphyseal fracture healing model at the tibial in rat. Langenbecks Arch Surg 2010; 395: 163-172.

  37. Bukata SV, Puzas JE. Orthopedic uses of teriparatide. Osteoporos Rep 2010; 8: 28-33.

  38. Andreassen TT, Ejersted C, Oxkund H. Intermittent parathyroid hormone (I-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999; 14: 960-968.

  39. Goldhahn J et al. Fracture healing with current and new osteoporosis treatments. Implications for fractures healing of current and new osteoporosis treatments: An ESCEO Consensus Paper. Calcif Tissue Int. Published on line: 28 March 2012.

  40. Li YF, Luo E, Feng G et al. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int 2009; 21: 1189-1897.

  41. Alegre DN, Ribeiro C, Souza C et al. Possible benefits of strontium ranelate in complicated long bone fractures. Rheumatol Int 2012; 32: 439-443.

  42. Li X, Ominsky MS, Warmington KS et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-588.

  43. Chen Y, Whetstone HC, Lin AC et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair implications for therapy to improve bone healing. PLoS Med 2007; 4: e249.

  44. Prisby RD, Lafage-Proust MH, Malaval L, Belli A, Vico L. Effects of whole body vibration on the skeleton and other organ systems in man and animal models, what we know and what need to know. Ageing Res Rev 2008; 7: 319-329.

  45. Slatkosvka L et al. Effect of 12 months of whole-body vibration therapy on bone density and structure in postmenopausal women. Annals of Internal Medicine 2010; 151 (10): 668-679.



>Revistas >Anales Médicos de la Asociación Médica del Centro Médico ABC >Año2012, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019